Everything below concerns storage stability. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-08. Numbers and descriptions here follow the published literature rather than marketing material.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
=== Recombinant human insulin === Recombinant human insulin has almost completely replaced insulin obtained from animal sources (e.g. pigs and cattle) for the treatment of type 1 diabetes. A variety of different recombinant insulin preparations are in widespread use. Recombinant insulin (insulin aspart) is synthesized by inserting the human insulin gene into E. coli or yeast (Saccharomyces cerevisiae), which then produces insulin for human use. Insulin produced by E. coli requires further post translational modifications (e.g. glycosylation) whereas yeasts are able to perform these modifications themselves by virtue of being more complex host organisms. The advantage of recombinant human insulin is after chronic use patients do not develop an immune defence against it the way animal-sourced insulin stimulates the human immune system.
=== Aldoses and ketoses === Monosaccharides which contain an aldehyde group are known as aldoses, and those with a ketone group are known as ketoses. The aldehyde can be oxidized via a redox reaction in which another compound is reduced. Thus, aldoses are reducing sugars. Sugars with ketone groups in their open chain form are capable of isomerizing via a series of tautomeric shifts to produce an aldehyde group in solution. Therefore, ketones like fructose are considered reducing sugars but it is the isomer containing an aldehyde group which is reducing since ketones cannot be oxidized without decomposition of the sugar backbone. This type of isomerization is catalyzed by the base present in solutions which test for the presence of reducing sugars.
=== Human capital === In order to benefit from the advent of digital agriculture, farmers must develop new skills. As Bronson (2018) notes, "training a rural work-force in Internet technology skills (e.g., coding) is obviously a key part of agricultural "modernization." Integration into the digital economy requires basic literacy (ability to read) and digital literacy (ability to use digital devices to improve welfare). In many instances, benefiting from digital content also requires English literacy or familiarity with another widely spoken language. Digital agriculture developers have designed ways around these barriers, such as ICTs with audio messages and extension videos in local languages. However, more investment in human capital development is needed to ensure all farmers can benefit from digital agriculture. Fostering human capital in the form of innovation also matters for the spread of digital agriculture. Some characterize digital agriculture innovation, a knowledge- and skills-intensive process, as concentrated in "Big Ag" companies and research universities. However, others describe small-scale entrepreneurs as the "heart of the action." In 2018, ag-tech innovation attracted $1.9 billion in venture capital, and the sector has grown significantly in the last 10 years. Although digital agriculture may be concentrated in a few developed countries because of "structure, institutional, and economic barriers," ag-tech startups have experienced significant growth in Africa, the Caribbean and Pacific, Asia, and Latin America as well.
== SE == se – (s) Northern Sami language (ISO 639-1 code) Se – (s) Selenium SE (s) Seychelles (FIPS 10-4 country code) (i) Societas Europaea (form of business organization in the EU) South-east (s) Sweden (ISO 3166 digram) (i) Synthetic Environment Systems engineering SEAD – (i) Suppression of Enemy Air Defence(s) SEADI – (i) Senior Executioner of Approved Driving Instructors SEAFDEC – (p) Southeast Asian Fisheries Development Center SEAL – (p) SEa-Air-Land SEAT – (a) Sociedad Española de Automóviles de Turismo (Spanish for "Spanish Touring Car Company") SEATO – (a) Southeast Asia Treaty Organization SeaWiFS – (p) Sea-Viewing Wide Field of View Sensor (satellite instrument) SEC (i) U.S. Securities and Exchange Commission (p) Security Southeastern Conference SECaaS - (p) Security-as-a-Service SECAM – (a) Séquentiel couleur à mémoire (French for "Colour Sequential with Memory"; TV standard, cf. NTSC, PAL) SECDEF – (p) (U.S.) Secretary of Defense SED – (i) CERDEC Software Engineering Directorate SEDRIS – (a) Synthetic Environment Data Representation and Interchange Specification SEE – (a) Small Emplacement Excavator SEG – (i) Society of Exploration Geophysicists SEG – (i) Special Escort Group SEK – (s) Swedish krona (ISO 4217 currency code) Selkent – (p) South East London & Kent Bus Company SELT – (a) Single Ended Line Test (ing) SEM (i/a) Sensor Employment Manager Switch to Email Mode, i.e.
Sources: en.wikipedia.org
Ataxia with oculomotor apraxia type 1 (AOA1), also known as early-onset ataxia with ocular motor apraxia and hypoalbuminemia, is a rare autosomal recessive disorder caused by mutations in the APTX gene. AOA1 usually begins as uncoordinated movements and ataxia at the age of four but can start manifesting between ages two and ten. Also, they develop oculomotor apraxia, dysarthric speech, myoclonic jerks, chorea, cognitive impairment, and neuropathy. Elevated levels of cholesterol, creatine kinase, and decreased levels of albumin can be seen. Patients usually start using wheelchair after 11 years since the onset of the symptoms. APTX gene codes for the protein Aprataxin, which might help DNA repair by the removal of adenylate groups from 5′-phosphate terminus at single-strand DNA nicks and gaps. It is most common in Japan and Portugal.
Wittman was reelected to the Virginia House of Delegates unopposed. On December 11, 2007, Wittman was first elected to the United States Congress to succeed the late congresswoman Jo Ann Davis, who died in October 2007. He was heavily favored in the special election due to the 1st's heavy Republican bent; it has been in Republican hands since 1977. The Independent candidate was Lucky Narain.
== Theory == Quantum dots are theoretically described as a point-like, or zero dimensional (0D) entity. Most of their properties depend on the dimensions, shape, and materials of which QDs are made. Generally, QDs present different thermodynamic properties from their bulk materials. One of these effects is melting-point depression. Optical properties of spherical metallic QDs are well described by the Mie scattering theory.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.